662 related articles for article (PubMed ID: 17183313)
1. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis.
Noguera-Troise I; Daly C; Papadopoulos NJ; Coetzee S; Boland P; Gale NW; Lin HC; Yancopoulos GD; Thurston G
Nature; 2006 Dec; 444(7122):1032-7. PubMed ID: 17183313
[TBL] [Abstract][Full Text] [Related]
2. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis.
Noguera-Troise I; Daly C; Papadopoulos NJ; Coetzee S; Boland P; Gale NW; Lin HC; Yancopoulos GD; Thurston G
Novartis Found Symp; 2007; 283():106-20; discussion 121-5, 238-41. PubMed ID: 18300417
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis.
Ridgway J; Zhang G; Wu Y; Stawicki S; Liang WC; Chanthery Y; Kowalski J; Watts RJ; Callahan C; Kasman I; Singh M; Chien M; Tan C; Hongo JA; de Sauvage F; Plowman G; Yan M
Nature; 2006 Dec; 444(7122):1083-7. PubMed ID: 17183323
[TBL] [Abstract][Full Text] [Related]
4. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting.
Lobov IB; Renard RA; Papadopoulos N; Gale NW; Thurston G; Yancopoulos GD; Wiegand SJ
Proc Natl Acad Sci U S A; 2007 Feb; 104(9):3219-24. PubMed ID: 17296940
[TBL] [Abstract][Full Text] [Related]
5. Delta-like 4/Notch signaling and its therapeutic implications.
Yan M; Plowman GD
Clin Cancer Res; 2007 Dec; 13(24):7243-6. PubMed ID: 18094402
[TBL] [Abstract][Full Text] [Related]
6. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.
Li JL; Sainson RC; Shi W; Leek R; Harrington LS; Preusser M; Biswas S; Turley H; Heikamp E; Hainfellner JA; Harris AL
Cancer Res; 2007 Dec; 67(23):11244-53. PubMed ID: 18056450
[TBL] [Abstract][Full Text] [Related]
7. New pathways and mechanisms regulating and responding to Delta-like ligand 4-Notch signalling in tumour angiogenesis.
Oon CE; Harris AL
Biochem Soc Trans; 2011 Dec; 39(6):1612-8. PubMed ID: 22103496
[TBL] [Abstract][Full Text] [Related]
8. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
Li JL; Sainson RC; Oon CE; Turley H; Leek R; Sheldon H; Bridges E; Shi W; Snell C; Bowden ET; Wu H; Chowdhury PS; Russell AJ; Montgomery CP; Poulsom R; Harris AL
Cancer Res; 2011 Sep; 71(18):6073-83. PubMed ID: 21803743
[TBL] [Abstract][Full Text] [Related]
9. The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions.
Hainaud P; Contrerès JO; Villemain A; Liu LX; Plouët J; Tobelem G; Dupuy E
Cancer Res; 2006 Sep; 66(17):8501-10. PubMed ID: 16951162
[TBL] [Abstract][Full Text] [Related]
10. The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth.
Thurston G; Noguera-Troise I; Yancopoulos GD
Nat Rev Cancer; 2007 May; 7(5):327-31. PubMed ID: 17457300
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function.
Patel NS; Li JL; Generali D; Poulsom R; Cranston DW; Harris AL
Cancer Res; 2005 Oct; 65(19):8690-7. PubMed ID: 16204037
[TBL] [Abstract][Full Text] [Related]
12. Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis?
Sainson RC; Harris AL
Trends Mol Med; 2007 Sep; 13(9):389-95. PubMed ID: 17822956
[TBL] [Abstract][Full Text] [Related]
13. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis.
Hellström M; Phng LK; Hofmann JJ; Wallgard E; Coultas L; Lindblom P; Alva J; Nilsson AK; Karlsson L; Gaiano N; Yoon K; Rossant J; Iruela-Arispe ML; Kalén M; Gerhardt H; Betsholtz C
Nature; 2007 Feb; 445(7129):776-80. PubMed ID: 17259973
[TBL] [Abstract][Full Text] [Related]
14. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching.
Suchting S; Freitas C; le Noble F; Benedito R; Bréant C; Duarte A; Eichmann A
Proc Natl Acad Sci U S A; 2007 Feb; 104(9):3225-30. PubMed ID: 17296941
[TBL] [Abstract][Full Text] [Related]
15. Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications.
Li JL; Harris AL
Front Biosci (Landmark Ed); 2009 Jan; 14(8):3094-110. PubMed ID: 19273260
[TBL] [Abstract][Full Text] [Related]
16. Bv8 regulates myeloid-cell-dependent tumour angiogenesis.
Shojaei F; Wu X; Zhong C; Yu L; Liang XH; Yao J; Blanchard D; Bais C; Peale FV; van Bruggen N; Ho C; Ross J; Tan M; Carano RA; Meng YG; Ferrara N
Nature; 2007 Dec; 450(7171):825-31. PubMed ID: 18064003
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition.
Dang DT; Chun SY; Burkitt K; Abe M; Chen S; Havre P; Mabjeesh NJ; Heath EI; Vogelzang NJ; Cruz-Correa M; Blayney DW; Ensminger WD; St Croix B; Dang NH; Dang LH
Cancer Res; 2008 Mar; 68(6):1872-80. PubMed ID: 18339868
[TBL] [Abstract][Full Text] [Related]
18. Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer.
Patel NS; Dobbie MS; Rochester M; Steers G; Poulsom R; Le Monnier K; Cranston DW; Li JL; Harris AL
Clin Cancer Res; 2006 Aug; 12(16):4836-44. PubMed ID: 16914569
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor as a survival factor in tumor-associated angiogenesis.
Affara NI; Robertson FM
In Vivo; 2004; 18(5):525-42. PubMed ID: 15523889
[TBL] [Abstract][Full Text] [Related]
20. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
Miles KM; Seshadri M; Ciamporcero E; Adelaiye R; Gillard B; Sotomayor P; Attwood K; Shen L; Conroy D; Kuhnert F; Lalani AS; Thurston G; Pili R
PLoS One; 2014; 9(11):e112371. PubMed ID: 25393540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
